ISTANBUL   Japan has conditionally approved the world’s first commercial regenerative medicine treatments developed from induced pluripotent stem (iPS) cells, a major milestone in advanced medical research, local media reported Friday. The decision allows the limited use of two therapies: ReHeart, developed by Cuorips Inc. to treat severe heart failure caused by ischemic cardiomyopathy, and Amchepry, created by Sumitomo Pharma Co. and Racthera Inc. to treat Parkinson’s disease, according to